Tag Archive for: biomanufacturing

Rentschler Biopharma announces largest single investment in the higher double-digit range at its headquarters in Germany for construction of a new buffer media facility in Laupheim.

Biomanufacturers must balance the development of new therapeutic modalities and reduce manufacturing costs while maintaining environmental responsibility. Efforts are centred on improving process robustness and efficiency and creating more flexible manufacturing facilities that can accommodate diverse biopharmaceutical products.

If you want to successfully guard against future pandemics, you’re going to need a good plan – and the right kind of vaccine producers. WACKER and CordenPharma have been commissioned by the German government to prepare their mRNA vaccine production lines for a new pandemic.

With the opening of a production centRE for RNA vaccines and therapeutics, German CDMO Wacker Biotech is expanding its expertise in the field of RNA active ingredients.

Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors. Furthermore, using them together with a powerful bioprocess controller like the BioFlo® 320 enables precise cell culture parameter control and seamless process transition to up to 40 L of working volume.

Danish industrial biotechnology startup Cellugy raises €4,9m with the ambition to replace petrochemicals in personal care products.

Danish CDMO 21st.BIO A/S has unveiled a new pilot plant facility to accelerate scaling of biotech processes ranging from food and beverages, agriculture, biomaterials, and biopharma.
  

  

Archaeal Power-to-biomethan producer Electrochaea GmbH has sold a BioCat bioreactor to the Danish CCU  specialist Again A/S.

Finnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit the start-up’s AaltoCell technology

Professionalism and quality are always at the forefront along the whole value chain: from gene to product. To pro-actively meet the evolving demand of the market to produce new assets Richter-Helm significantly increased its manufacturing capacities for biopharmaceutical products at its production site in Bovenau, Germany.